<DOC>
	<DOC>NCT00828672</DOC>
	<brief_summary>Phase II clinical trial, open-label, randomized, two arms, multicentre (possibly multinational). Academic, investigator initiated. To assess the activity of bevacizumab (AvastinTM) in combination with capecitabine (XelodaTM) and radiation therapy with or without oxaliplatin (EloxatinTM) in the pre-operative treatment of locally advanced rectal cancer, followed by TME (total mesorectal excision).</brief_summary>
	<brief_title>Phase II Study of Neo Adjuvant Treatment With Avastin, Xeloda and/or Eloxatin in Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Patient is at least 18 years of age Good organ function Locally advanced (according to RECIST criteria) adenocarcinoma of the rectum Evidence of distant metastases Contraindication for bevacizumab Pregnant or breastfeeding women.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>assess activity</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>capecitabine</keyword>
	<keyword>radiation therapy</keyword>
	<keyword>oxaliplatin</keyword>
	<keyword>pre-operative treatment</keyword>
	<keyword>TME (total mesorectal excision).</keyword>
</DOC>